Stevanato Group S.p.A. (STVN) Earnings
Stevanato Group S.p.A. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $0.14. STVN has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise +9.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $0.12 | $0.13 | +8.3% | $316M | +1.8% |
| Mar 4, 2026 | $0.20 | $0.21 | +5.0% | $403M | +28.2% |
| Nov 6, 2025 | $0.14 | $0.16 | +14.3% | $355M | -7.9% |
| May 8, 2025 | $0.10 | $0.11 | +10.0% | $281M | -6.7% |
| Mar 6, 2025 | $0.20 | $0.20 | +0.0% | $342M | +27.7% |
| May 9, 2024 | $0.12 | $0.09 | -27.3% | $254M | -15.6% |
| Mar 7, 2024 | $0.21 | $0.20 | -5.3% | $353M | +24.1% |
| Oct 31, 2023 | $0.16 | $0.16 | +0.0% | $286M | -25.5% |
| Jul 28, 2023 | $0.14 | $0.15 | +7.7% | $279M | -17.1% |
| May 4, 2023 | $0.13 | $0.12 | -8.3% | $259M | -12.8% |
| Mar 2, 2023 | $0.17 | $0.19 | +12.5% | $315M | +14.3% |
| Aug 4, 2022 | $0.12 | $0.12 | +0.0% | $245M | +2.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Franco Stevinato is recovering from an appendectomy and unable to join the call. - Started fiscal 2026 with strong momentum, 10% revenue growth on constant currency basis. Biopharmaceutical and diagnostic solution segment drove growth, especially syringes with over 20% Y/Y increase, and other categories like cartridges and vials. - GLP-1s accounted for ~21%-22% of total company revenue in Q1 2026, driving 15% increase in biologics revenue. - Converted underutilized ready-to-use vial line to ready-to-use cartridge line at Piombino d'Ese to meet market demand. - Engineering segment saw initial margin improvement from business optimization plan but low backlog and slow new order intake. - Focused on scaling growth investments in U.S. and Italy. In Fishers, customer validations/audits ongoing, U.S. team expanding, contract manufacturing build-out on schedule. In Latina, ramping up high-value syringe capacity and preparing for easy-fill cartridge expansion with next-generation RTU-400 lines.
Guidance
Maintaining 2026 guidance with revenue in range of 1,260,000,000 - 1,290,000,000, adjusted EBITDA between 331.8 million and 346.9 million, and adjusted diluted EPS between 59 cents and 63 cents. Expect second half of the year stronger than first half for engineering segment. BDS segment gross profit margin expected to be in line or slightly better than last year.
Segment performance
In the first quarter of 2026, revenue grew 10% at constant currency and 7% on a reported basis to 273.6 million. BDS segment revenue increased 16% at constant currency and 13% on a reported basis to 249 million, driven by strong growth in high-value syringes and other product categories. High value solutions grew 17% to 128.6 million, representing approximately 52% of segment revenue. Other containment and delivery solutions increased 9% to 120.3 million. Gross profit in BDS increased by 1.2 million but gross profit margin decreased by 300 basis points to 28.3%. Operating profit in BDS increased 6% to 44.1 million with an operating profit margin of 17.7%. Engineering segment revenue decreased 31% to 24.6 million. Gross profit margin improved 460 basis points to 15.3% and operating profit margin increased 190 basis points to 6.6%.
Analyst Q&A
Q: (Michael Ricekin, Bank of America) On GLP-1s, volume visibility, durability and risk from orals.
A: Believes GLP market will continue to grow, volumes predictable in 2026 due to contractual commitments, sees 70% market opportunities in injectables.
Q: (Larry Solo, CJS Securities) On BDS segment margins in Q1 and GPM for the year.
A: BDS gross profit margin expected to be in line or slightly better than last year, factors include mix, depreciation, currency headwinds, tariffs and service from last year.
Q: (Patrick Donnelly, CT) On engineering segment, orders materializing slower, initiatives.
A: Progressing with operational improvement, winning contracts, expecting second half stronger, reiterating focus on improving efficiency.
Q: (Paul Knight, KeyBank) On biologics business growing 15% vs market 10%, why premium growth.
A: GLPs significant driver, biologics revenue from wide-ranging areas including MABs, biosimilars, etc., and ramp up of capacity.
Q: (matt larue william blair) On engineering segment, sales cycle extension, not losing share.
A: Adding sales and marketing BD resources, sales cycle lengthened due to more disciplined procurement.
Q: (Doug Shankal of Wolf Research) On disaggregating GLP-1 vs non-GLP-1 growth in HBS, inflationary pressures, margins.
A: GLP-1 grew slightly more than 20%, non-GLP-1 biologics up mid-single digits, inflationary pressures monitored, working with customers to transfer pressure, Q1 numbers in line with expectations.
Q: (Callum Tishmarsh, Morgan Stanley) On mid-teens GLP growth assumption, lag from site acceptance tests to revenue.
A: 2026 growth driven by syringes, cartridges also growing, SAT important but revenue recognition impacts timing.
Q: (Curtis Moylan, BNP Paribas Exxon) On easy fill vials dynamics, underutilization, further investment in cartridges.
A: Easy fill vials grew, flexibility of engineering team addressing capacity, fully booked on cartridges, new converted line to come into service by end of quarter.